14 MARCH 2022 Bionomics Receives $264k Licensing Revenue from CTx Bionomics Limited (ASX:BNO, NASDAQ:BNOX), (Bionomics or the Company) a clinical stage biopharmaceutical company, is pleased to announce that it has received A$263,634 in licensing revenue from its successful participation in the Cancer Therapeutics CRC (CTx). The CTx has licensed two targets to Pfizer Inc. under a potential US$460M deal. The Company is well funded to continue advancing BNC210 through ongoing clinical studies for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD), with U.S. Food and Drug Administration (FDA) Fast Track designation for
BNO Price at posting:
6.7¢ Sentiment: Buy Disclosure: Held
